Apolipoprotein E polymorphism modulation of asymmetric dimethylarginine in hypertensive patients is determined by renal function

Página do item simplificado
dc.citation.volume15
dc.contributor.authorMarrocos, Mauro Sergio Martins [UNIFESP]
dc.contributor.authorTeixeira, Andrei Alkmin [UNIFESP]
dc.contributor.authorQuinto, Beata Marie [UNIFESP]
dc.contributor.authorCarmona, Silmara de Melo [UNIFESP]
dc.contributor.authorKuniyoshi, Mariana [UNIFESP]
dc.contributor.authorRodrigues, Cassio Jose [UNIFESP]
dc.contributor.authorDalboni, Maria Aparecida [UNIFESP]
dc.contributor.authorManfredi, Silvia [UNIFESP]
dc.contributor.authorCanziani, Maria Eugenia [UNIFESP]
dc.contributor.authorBatista, Marcelo Costa [UNIFESP]
dc.coverageLondon
dc.date.accessioned2020-10-30T18:46:38Z
dc.date.available2020-10-30T18:46:38Z
dc.date.issued2016
dc.description.abstractBackground: Endothelial dysfunction is considered an early step of atherosclerotic vascular disease. Asymmetric dimethylarginine (ADMA), the main endogenous inhibitor of nitric oxide synthase (NOS), plays a critical role in the process of atherosclerosis in a uremic environment. Increased plasma ADMA not only works as a cardiovascular morbidity biomarker but it is also involved in the genesis of atherosclerosis in renal disease. Considering the relationships of apolipoprotein E(ApoE) polymorphism with LDL cholesterol (LDL-C) levels and coronary risk, it is possible that it brings on susceptibility to endothelial dysfunction and atherogenesis seen on uremia. Methods: Six hundred twenty patients were stratified according to glomerular filtration rate (GFR) estimated by Chronic Kidney Disease Epidemiology Collaboration (CKDEPI) formula: group I > 60 mL/min, group II <= 60 mL/min and > 15 mL/min, and group III <= 15 mL/min or in hemodialysis. Polymorphic ApoE analysis was performed by polymerase chain reaction amplification (PCR). Plasma ADMA levels were measured by high performance liquid chromatography (HPLC). Groups were compared on clinical and laboratory characteristics as well as allele and genotype distribution towards. Results: The epsilon 2 allele of ApoE was present in 62 (10.3 %) patients, epsilon 3 allele in 581 (96.2 %), and epsilon 4 allele in 114 (18.9 %). Their distribution among the 3 groups was uniform. Such uniformity was not observed when we considered endothelial function measured by asymmetric dimethylarginine. In group III, the frequency of epsilon 4 allele was significantly lower in the third tertile compared with the first tertile (14.7 versus 53.3 %, P = 0.000; Pearson chisquare). In groups I and II, there was no difference in allele frequency according to ADMA levels. This association remained significant even after confouding factors corrections (OR 0.329, 95 % CI 0.155 - 0.699, P = 0.004). Conclusions: The results of this study shows that the frequency of epsilon 4 allele of ApoE is significantly lower among hypertensive patients on hemodialysis with the highest levels of ADMA. Uremia is capable of determining lower plasma ADMA levels in hypertensive epsilon 4 allele carriers.en
dc.description.affiliationUniv Fed Sao Paulo, Nephrol Div, R Pedro de Toledo 781 14 Andar, BR-04039032 Sao Paulo, Brazil
dc.description.affiliationTufts Univ, New England Med Ctr, Nephrol Div, Boston, MA 02111 USA
dc.description.affiliationHosp Israelita Albert Einstein, Res & Educ Inst, Sao Paulo, SP, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Nephrol Div, R Pedro de Toledo 781 14 Andar, BR-04039032 Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipFundo de Amparo a Pesquisa do Estado de Sao Paulo/FAPESP
dc.format.extent-
dc.identifierhttps://doi.org/10.1186/s12944-016-0182-y
dc.identifier.citationLipids In Health And Disease. London, v. 15, p. -, 2016.
dc.identifier.doi10.1186/s12944-016-0182-y
dc.identifier.fileWOS000368498000001.pdf
dc.identifier.issn1476-511X
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/58546
dc.identifier.wosWOS:000368498000001
dc.language.isoeng
dc.publisherBiomed Central Ltd
dc.relation.ispartofLipids In Health And Disease
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAsymmetric Dimethylarginineen
dc.subjectApolipoprotein Een
dc.subjectPolymorphismen
dc.subjectAtherogenesisen
dc.subjectChronic Kidney Diseaseen
dc.titleApolipoprotein E polymorphism modulation of asymmetric dimethylarginine in hypertensive patients is determined by renal functionen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
WOS000368498000001.pdf
Tamanho:
562.73 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
EPM - Artigos